Dr. Francisco Jimenez Carcamo, MD
What this data tells you about Dr. Jimenez Carcamo
Dr. Francisco Jimenez Carcamo is a cardiovascular disease in South Miami, FL, with 19 years in practice. Based on federal Medicare data, Dr. Jimenez Carcamo performed 4,325 Medicare services across 1,958 unique beneficiaries.
Between the years covered by Open Payments, Dr. Jimenez Carcamo received a total of $335,160 from 37 pharmaceutical and/or device companies across 599 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in cardiovascular disease. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Jimenez Carcamo is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
Medicare Practice Summary
Medicare Utilization ↗Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Remote patient monitoring management, 20 min/month | 851 | $38 | $105 |
| Remote patient monitoring device, 30 days | 612 | $40 | $110 |
| Office visit, established patient (30-39 min) | 593 | $102 | $270 |
| Office visit, established patient (20-29 min) | 438 | $73 | $195 |
| Electrocardiogram (EKG), 12-lead | 389 | $11 | $31 |
| Management using the results of remote vital sign monitoring per calendar month, each additional 20 minutes | 331 | $32 | $91 |
| EKG interpretation and report | 315 | $7 | $20 |
| Echocardiogram, transthoracic | 177 | $155 | $424 |
| Regadenoson injection (Lexiscan) for heart stress test | 124 | $43 | $110 |
| Technetium tc-99m tetrofosmin, diagnostic, per study dose | 70 | $351 | $500 |
| New patient office visit (45-59 min) | 65 | $126 | $360 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 54 | $53 | $150 |
| Ultrasound of heart, follow-up | 47 | $76 | $224 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 35 | $358 | $960 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system | 29 | $57 | $116 |
| Evaluation of implantable heart and blood vessel monitoring system | 28 | $38 | $79 |
| Remote monitoring of physiologic parameters, initial set-up and patient education on use of equipment | 23 | $16 | $35 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system | 20 | $43 | $83 |
| Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | 18 | $21 | $57 |
| Electrocardiogram (ecg) up to 30 days continuous with transmission of patient triggered events with review and report by health care professional | 18 | $687 | $1,860 |
| Initial hospital admission, high complexity | 15 | $124 | $430 |
| Insertion of tube in right heart chambers for measurement | 14 | $120 | $327 |
| 3d radiographic procedure | 13 | $8 | $19 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 12 | $53 | $160 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 12 | $192 | $490 |
| Test to measure rate of airflow | 11 | $32 | $85 |
| Test for exercise-induced heart and lung stress | 11 | $128 | $352 |
Industry Payment Transparency
Open Payments through 2024 ↗Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
Payments by company (2024)
Associated products mentioned in payments ›
The majority of payments (94%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in cardiovascular disease and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 1% for cardiovascular disease in FL.
Geographic Context
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Jimenez Carcamo is a clinical cardiology specialist, with above-average Medicare volume (top 25% in FL), and high industry engagement (speaking/promotional, top 1%), with 19 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Jimenez Carcamo experienced with remote patient monitoring management, 20 min/month?
Does Dr. Jimenez Carcamo receive payments from pharmaceutical companies?
How do Dr. Jimenez Carcamo's costs compare to other cardiovascular diseases in South Miami?
What does Data Coverage mean?
Is this data up to date?
Explore related providers
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology